For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use ...

Some weight-loss and diabetes drugs can treat obesity when combined with exercise, a healthy diet, and counseling, according to WHO's first guidance on these medicines. The recommendations come amid ...

GLP-1 medicines cause malnutrition in 22% of patients. Multivitamins are often inadequate. Patients need dietitian support ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, liraglutide, and tirzepatide are widely prescribed ...

A session at the AHA Scientific Sessions 2025 focused on the latest groundbreaking trails in cardiometabolic therapies.

MetaVia, Inc. (NASDAQ:MTVA) is currently conducting a Phase 1 clinical trial of DA-1726, the company’s oxyntomodulin (OXM) analog that is a dual agonist of the glucagon-like peptide-1 receptor (GLP1R) ...

The oral small-molecule glucagon-like peptide 1 (GLP-1) receptor agonist orforglipron demonstrates superior weight loss as an ...

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) ...

The guideline specifies that drugs alone are not enough and emphasizes the need for behavioral and lifestyle interventions.

ATLANTA -- An investigational quadruple receptor agonist led to a substantial reduction in total body weight with minimal gastrointestinal adverse effects and no observed muscle loss, according to a ...